Biomarker Assay Validation in Healthy Smokers and COPD Smokers and Ex-smokers

NCT ID: NCT02490358

Last Updated: 2016-02-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-06-30

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will collect sputum samples from healthy smokers, COPD smokers and COPD ex-smokers to analyse biomarkers of inflammation

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Healthy smoking subjects

No interventions assigned to this group

2

COPD smoking subjects

No interventions assigned to this group

3

COPD ex-smoker subjects

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Must have signed an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
2. Be between 18 and 75 years of age, inclusive, at informed consent.
3. Healthy as determined by a physician, based on medical history and physical examination.
4. Must have smoked regularly in the 12-month period preceding the screening visit and have a pack history of ≥ 5 pack years (number of pack years = number of cigarettes per day/20 x number of years smoked).


1. Must have signed an informed consent indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
2. Aged between 40 and 75 years of age inclusive, at the time of signing the informed consent.
3. COPD diagnosis: Subjects with a diagnosis of COPD as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines (Celli, 2004). Symptoms must be compatible with COPD for at least 1 year prior to screening and post-bronchodilator spirometry readings at screening:

* Post-bronchodilator FEV1/FVC ratio of \<0.7
* Post-bronchodilator FEV ≥40 % and ≤80 % of predicted normal values calculated using NHANES reference equations.

Additional Inclusion for Smoking COPD Subjects 1. Must have smoked regularly in the 12-month period preceding the screening visit and have a pack history of ≥ 5 pack years (number of pack years = number of cigarettes per day/20 x number of years smoked).

Exclusion Criteria

1. Upper or lower respiratory tract infection within 4 weeks of the screening visit.
2. Positive test for alcohol at screening.
3. Taking prescription medication in the 14 days before screening.
4. Subjects whose primary consumption of tobacco is via methods other than cigarettes (manufactured or self-rolled). Primary methods of tobacco consumption that are excluded include, but are not limited to pipes, cigars and e-cigarettes.
5. Subjects who are unable to produce a total weight of at least 0.1 grams (g) of selected sputum at screening
6. Urinary cotinine levels at screening \< 30 ng/ml.
7. Subject is mentally or legally incapacitated.
8. Subject is an employee of the Sponsor or contract research organization (CRO), or a relative of an employee of the Sponsor or CRO.
9. Any other reason that the Investigator considers makes the subject unsuitable to participate.


1. Upper or lower respiratory tract infection within 4 weeks of the screening visit.
2. Positive test for alcohol at screening.
3. Subjects who are unable to produce a total weight of at least 0.1g of selected sputum at screening.
4. Subject is mentally or legally incapacitated.
5. Subject is an employee of the Sponsor or contract research organization (CRO), or a relative of an employee of the Sponsor or CRO.
6. Any other reason that the Investigator considers makes the subject unsuitable to participate.
7. A history of life-threatening COPD including Intensive Care Unit admission and/or requiring intubation.
8. Taking theophylline in the 28 days before screening
9. Change in COPD medication in the 28 days before screening
10. Taking oral steroids in the 28 days before screening

Additional Exclusion Criterion for Smoking COPD Subjects

1. Subjects whose primary consumption of tobacco is via methods other than cigarettes (manufactured or self-rolled). Primary methods of tobacco consumption that are excluded include, but are not limited to pipes, cigars and e-cigarettes.
2. Urinary cotinine levels at screening \< 30 ng/ml.

Additional Exclusion Criterion for Ex-Smoking COPD Subjects

1\. The subject is a smoker (regular or irregular), or has smoked or used nicotine-containing products within the 6 months prior to screening.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Babraham Institute Enterprise Limited

OTHER

Sponsor Role collaborator

Respivert Ltd

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ginny Norris, Dr

Role: STUDY_DIRECTOR

Respivert Ltd

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ENA003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Markers of COPD Exacerbations
NCT05315674 RECRUITING
COPD in the Time of COVID-19
NCT04407598 UNKNOWN
Study of COPD Subgroups and Biomarkers
NCT01969344 ACTIVE_NOT_RECRUITING